Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
Clin. transl. oncol. (Print)
; 20(8): 1072-1079, ago. 2018. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-173691
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Background:
Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. Patients andmethods:
Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry.Results:
A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months).Conclusion:
Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognosticRESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
Base de dados:
IBECS
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Anticorpos Monoclonais Humanizados
/
Neoplasias Pulmonares
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Arnau de Vilanova/Spain
/
Hospital Dr Peset/Spain
/
Hospital General Universitario de Valencia/Spain
/
Hospital General de Elche/Spain
/
Hospital Lluis Alcanyís/Spain
/
Hospital Provincial de Castellón/Spain
/
Hospital Universitari I Politècnic La Fe/Spain
/
Hospital Universitario Fundación Alcorcón/Spain
/
Hospital Virgen de los Lirios/Spain
/
Hospital de Manises/Spain